Volume 23, Issue 5 (Iranian South Medical Journal 2020)
Iran South Med J 2020, 23(5): 442-454 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Alishahi A, Zargar M, Ghaemi A, Fotouhi F, Zolfaghari M R. Design, Production, and Evaluation of Virosomes from H1N1 Influenza Virus. Iran South Med J 2020; 23 (5) :442-454
URL: http://ismj.bpums.ac.ir/article-1-1350-en.html
URL: http://ismj.bpums.ac.ir/article-1-1350-en.html
1- Department of Microbiology, School of Basic Science, Qum Branch, Islamic Azad University, Qom, Iran
2- Department of Influenza and other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran , a_ghaem@pasteur.ac.ir
3- Department of Influenza and other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
2- Department of Influenza and other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran , a_ghaem@pasteur.ac.ir
3- Department of Influenza and other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
Abstract: (2413 Views)
Background: The last two decades witnessed the spread of the first generation of influenza viruses. Influenza virosomes are promising tools in vaccine and immunotherapy programs because of their applications in various medical fields. The aim of the present study was to construct cationic virosomes derived from
influenza virus using dialyzable detergent (DCPC) and cationic lipid (DOTAP) in vitro.
Materials and Methods: Influenza A / Puerto Rico / 34.8 (H1N1) strain was propagated in MDCK cell line. The influenza virus envelope was dissolved using DCPC as a dialyzable detergent, and finally it was removed by dialysis and the cationic virosome was synthesized through adding cationic lipid (DOTAP). Cytotoxicity and presence of HA and NA proteins were evaluated by cell viability assay (MTT assay) and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), respectively. Also, macroscopic and morphology studies of virosomes were performed by transmission electron microscopy (TEM).
Results: The final concentration of virosomes was 1.5 mg/ml. The presence of HA and NA proteins was confirmed by SDS-PAGE. Cell survival was significantly decreased after 48 hours of treatment with
different concentrations of cationic virosomes (P<0.05).
Conclusion: The use of a detergent (DCPC) and also a cationic lipid (DOTAP) is an effective procedure for reconstruction of influenza virus envelope without any alteration in surface glycoproteins (HA, NA). The methoed used in the present study for producing influenza virosome will be a promising candidate for
developing influenza vaccines.
influenza virus using dialyzable detergent (DCPC) and cationic lipid (DOTAP) in vitro.
Materials and Methods: Influenza A / Puerto Rico / 34.8 (H1N1) strain was propagated in MDCK cell line. The influenza virus envelope was dissolved using DCPC as a dialyzable detergent, and finally it was removed by dialysis and the cationic virosome was synthesized through adding cationic lipid (DOTAP). Cytotoxicity and presence of HA and NA proteins were evaluated by cell viability assay (MTT assay) and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), respectively. Also, macroscopic and morphology studies of virosomes were performed by transmission electron microscopy (TEM).
Results: The final concentration of virosomes was 1.5 mg/ml. The presence of HA and NA proteins was confirmed by SDS-PAGE. Cell survival was significantly decreased after 48 hours of treatment with
different concentrations of cationic virosomes (P<0.05).
Conclusion: The use of a detergent (DCPC) and also a cationic lipid (DOTAP) is an effective procedure for reconstruction of influenza virus envelope without any alteration in surface glycoproteins (HA, NA). The methoed used in the present study for producing influenza virosome will be a promising candidate for
developing influenza vaccines.
Type of Study: Original |
Subject:
Microbiology and Immunology
Received: 2020/03/10 | Accepted: 2020/07/7 | Published: 2020/11/7
Received: 2020/03/10 | Accepted: 2020/07/7 | Published: 2020/11/7
References
1. Rabieian P, Zareei N, Abbaszadeh M, et al. Survey of Hematologic Markers of Influenza in Bushehr. Iran South Med J 2016; 19(5): 888-94. (Persian) [DOI:10.18869/acadpub.ismj.19.5.888]
2. Paget J, Spreeuwenberg P, Charu V, et al. Global Mortality Associated With Seasonal Influenza Epidemics: New Burden Estimates And Predictors From The Glamor Project. J Glob Health 2019; 9(2): 020421. [DOI:10.7189/jogh.09.020421]
3. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune Responses To Influenza Virus Infection. Virus Res 2011; 162(1-2): 19-30. [DOI:10.1016/j.virusres.2011.09.022]
4. Müllbacher A, Ada G, Tha Hla R. Gamma‐ Irradiated Influenza A Virus Can Prime For A Cross‐Reactive And Cross‐Protective Immune Response Against Influenza A Viruses. Immunol Cell Biol 1988; 66(2): 153-7. [DOI:10.1038/icb.1988.19]
5. Babb R, Chan J, Khairat JE, et al. GammaIrradiated Influenza A Virus Provides Adjuvant Activity To A Co-Administered Poorly Immunogenic SFV Vaccine In Mice. Front Immunol 2014; 5: 267. [DOI:10.3389/fimmu.2014.00267]
6. Furuya Y, Regner M, Lobigs M, et al. Effect Of Inactivation Method On The Cross-Protective Immunity Induced By Whole 'Killed'influenza A Viruses And Commercial Vaccine Preparations. J Gen Virol 2010; 91(6): 1450-60. [DOI:10.1099/vir.0.018168-0]
7. Wilschut J, Mcelhaney J, Palache A. Rapid Reference Influenza. 2nd ed. London: Elsevier Health Sciences, 2006.
8. Babar MM, Sadaf Zaidi N, Kazi AG, et al. Virosomes-Hybrid Drug Delivery Systems. J Antivir Antiretrovir 2013; 5(7): 166-72.
9. Sercombe L, Veerati T, Moheimani F, et al. Advances And Challenges Of Liposome Assisted Drug Delivery. Front Pharmacol 2015; 6: 286. [DOI:10.3389/fphar.2015.00286]
10. Jennings GT, Bachmann MF. The Coming Of Age Of Virus-Like Particle Vaccines. Biol Chem 2008; 389(5): 521-36. [DOI:10.1515/BC.2008.064]
11. Kalra N, Dhanya V, Saini V, et al. Virosomes: As A Drug Delivery Carrier. Am J Adv Drug Deliv 2013; 1(1): 29-35.
12. Mischler R, Metcalfe IC. Inflexal® V a Trivalent Virosome Subunit Influenza Vaccine: Production. Vaccine 2002; 20(Suppl 5): B17-23. [DOI:10.1016/S0264-410X(02)00512-1]
13. Moser C, Amacker M, Kammer AR, et al. Influenza Virosomes As A Combined Vaccine Carrier And Adjuvant System For Prophylactic And Therapeutic Immunizations. Expert Rev Vaccines 2007; 6(5): 711-21. [DOI:10.1586/14760584.6.5.711]
14. Cusi MG. Applications Of Influenza Virosomes As A Delivery System. Hum Vaccin 2006; 2(1): 1-7. [DOI:10.4161/hv.2.1.2494]
15. Huckriede A, Bungener L, Stegmann T, et al. The Virosome Concept For Influenza Vaccines. Vaccine 2005; 23(Suppl 1): S26-38. [DOI:10.1016/j.vaccine.2005.04.026]
16. Cryz SJ, Glück R. Immunopotentiating Reconstituted Influenza Virosomes As A Novel Antigen Delivery System. Dev Biol Stand 1998; 92: 219-23.
17. González-Jara P, Fraile A, Canto T, et al. The Multiplicity Of Infection Of A Plant Virus Varies During Colonization Of Its Eukaryotic Host. J Virol 2009; 83(15): 7487-94. [DOI:10.1128/JVI.00636-09]
18. Wickramasinghe S, Kalbfuss B, Zimmermann A, et al. Tangential Flow Microfiltration And Ultrafiltration For Human Influenza A Virus Concentration And Purification. Biotechnol Bioeng 2005; 92(2): 199-208. [DOI:10.1002/bit.20599]
19. Kalbfuss B, Genzel Y, Wolff M, et al. Harvesting And Concentration Of Human Influenza A Virus Produced In Serum‐Free Mammalian Cell Culture For The Production Of Vaccines. Biotechnol Bioeng 2007; 97(1): 73-85. [DOI:10.1002/bit.21139]
20. Killian ML. Hemagglutination Assay For Influenza Virus. In: Spackman E, editors. New York: Humana Press-Animal Influenza Virus, 2014, 3-9. [DOI:10.1007/978-1-4939-0758-8_1]
21. De Jonge J, Leenhouts JM, Holtrop M, et al. Cellular Gene Transfer Mediated By Influenza Virosomes With Encapsulated Plasmid DNA. Biochem J 2007; 405(1): 41-9. [DOI:10.1042/BJ20061756]
22. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein Measurement With The Folin Phenol Reagent. J Biol Chem 1951; 193(1): 265-75. [DOI:10.1016/S0021-9258(19)52451-6]
23. Peterson GL. A Simplification Of The Protein Assay Method Of Lowry Et Al. Which Is More Generally Applicable. Anal Biochem 1977; 83(2): 346-56. [DOI:10.1016/0003-2697(77)90043-4]
24. Mosmann T. Rapid Colorimetric Assay For Cellular Growth And Survival: Application To Proliferation And Cytotoxicity Assays. J Immunol Methods 1983; 65(1-2): 55-63. [DOI:10.1016/0022-1759(83)90303-4]
25. Laemmli U. Most Commonly Used Discontinuous Buffer System For SDS Electrophoresis. Nature 1970; 227: 680-6. [DOI:10.1038/227680a0]
26. Beg S, Samad A, Nazish I, et al. Colloidal Drug Delivery Systems In Vaccine Delivery. Curr Drug Targets 2013; 14(1): 123-37. [DOI:10.2174/138945013804806523]
27. Schwendener RA. Liposomes As Vaccine Delivery Systems: A Review Of The Recent Advances. Ther Adv Vaccines 2014; 2(6): 159-82. [DOI:10.1177/2051013614541440]
28. Paternostre M, Viard M, Meyer O, et al. Solubilization And Reconstitution Of Vesicular Stomatitis Virus Envelope Using Octylglucoside. Biophys J 1997; 72(4): 1683-94. [DOI:10.1016/S0006-3495(97)78814-3]
29. Paternostre MT, Lowy RJ, Blumenthal R. pH‐ Dependent Fusion Of Reconstituted Vesicular Stomatitis Virus Envelopes With Vero Cells Measurement By Dequenching Of Fluorescence. FEBS Lett 1989; 243(2): 251-8. [DOI:10.1016/0014-5793(89)80139-5]
30. Mohammadzadeh Y, Gholami S, Rasouli N, et al. Introduction Of Cationic Virosome Derived From Vesicular Stomatitis Virus As A Novel Gene Delivery System For sf9 Cells. J Liposome Res 2017; 27(2): 83-9. [DOI:10.3109/08982104.2016.1144205]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
